Boston Scientific Assessed $431M in Patent Suit
Robert Buderi2/12/08
A Texas jury found against Natick, MA-based Boston Scientific (NYSE: BSX) in a patent infringement suit involving drug-eluting stent products, awarding $431 million in damages to its opponent, the company announced today. The verdict, from a U.S. District Court jury in Marshall, Texas, found that the firm’s Taxus Express and Taxus Liberte stent products infringe a patent held by Dr. Bruce Saffran, and that Saffran’s patent is valid, the company reported in a statement. Boston Scientific said it would seek to overturn the verdict, and, if unsuccessful, that it would appeal the decision.
Bob is Xconomy's founder and editor in chief. You can e-mail him at bbuderi@xconomy.com, call him at 617.500.5926, or follow him on Twitter at http://twitter.com/bbuderi.
